A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak et al. · New England Journal of Medicine · 2001 · 11.5K citations · Full text

Medicine, Oncology, Pharmacology +10

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Charles L. Vogel · Journal of Clinical Oncology · 2002 · 3K citations

Medicine, Oncology, Pharmacology +17

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Melody Cobleigh, Charles L. Vogel, Debu Tripathy et al. · Journal of Clinical Oncology · 1999 · 2.8K citations

Medicine, Oncology, Pharmacology +17

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Raphael Clynes, Terri L. Towers, Leonard G. Presta et al. · Nature Medicine · 2000 · 2.7K citations

Medicine, Cancer Biology, Oncology +15

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Yoichi Nagata, Keng‐Hsueh Lan, Xiaoyan Zhou et al. · Cancer Cell · 2004 · 1.9K citations · Full text

Medicine, Cancer Biology, Oncology +14